Maverick Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Maverick Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,480	Closed	-$721K	–	692
2020 Q4	$721K	Buy	+13,480	New	+$669K	0.01%	290

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Maverick Capital's ACAD Position: Q1 2021 in Review

Maverick Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 13,480 shares — an estimated $721K sold.

Maverick Capital first reported a position in ACAD in Q4 2020 and held it in 1 quarter. The position peaked at $721K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Maverick Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Maverick Capital sold 13,480 Acadia Pharmaceuticals shares in Q1 2021, an estimated $721K.
Maverick Capital first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Maverick Capital's Acadia Pharmaceuticals position peaked at $721K in Q4 2020.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.